In this special ECD webinar, Dr. Jerome Razanamahery, an internal medicine doctor at Dijon University Hospital, an ECD referral care center, talks about Erdheim-Chester Disease (ECD). He explains what ECD is, why it can be hard to diagnose, and how new targeted...
Together, We Move Forward From the Erdheim-Chester Disease Global Alliance As we step into 2025, the Erdheim-Chester Disease Global Alliance (ECDGA) reflects on another meaningful year of connection, progress, and unwavering commitment to our mission. From our...
The ECD Global Alliance is pleased to announce that registration is now open for the 2026 Medical Symposium, held at the Marnix E. Heersink Conference Center at the University of Alabama at Birmingham (UAB). Early bird registration is available until February 1, 2026....
A new study from Memorial Sloan Kettering Cancer Center highlights the promise of ulixertinib, a targeted therapy drug that blocks ERK, for treating certain forms of histiocytosis, including Erdheim-Chester Disease (ECD). Led by Dr. Eli Diamond, a member of the ECDGA...
The Erdheim-Chester Disease Global Alliance (ECDGA) is issuing a final call for Letters of Intent (LOIs) for the 2025 research grant. The application period closes tomorrow, so there is only one day left to submit. This annual funding opportunity supports innovative...
